USMCA pharmaceutical rules of origin (HTS Chapter 30) generally use tariff-shift – API to finished dosage form, or earlier transformations within USMCA territory. RVC rules apply for some categories. Generic and biosimilar products follow same rules as branded.
This guide covers USMCA / CUSMA rules of origin for the Pharmaceuticals sector. Sector-specific rules determine how goods qualify for preferential treatment.
Qualifying goods are exempt from Section 122 in 2026 – the central commercial advantage.
Tariff-shift API to FDF
Active Pharmaceutical Ingredient (API) classified at one HTS code; finished dosage form at another. The shift in USMCA territory supports origin.
Earlier transformations
Synthesis or fermentation in USMCA territory at earlier stages can also support origin.
Generic vs branded
Same USMCA rules apply. Section 232 pharma exemption for generics is separate.
Documentation
Manufacturing process flowcharts, batch records, supplier certificates for starting materials.
Frequently asked questions
How do I know if my product meets these rules?
Run an RVC analysis or tariff-shift analysis specific to your HS classification. We provide fixed-fee analyses for $4,500-$8,500 per product.
Are these rules the same in Canada (CUSMA)?
Yes. USMCA in the U.S. and CUSMA in Canada are the same agreement. Rules of origin are identical; implementing regulations differ slightly.
What documentation supports qualification?
Bill of materials, supplier certifications, manufacturing process records, RVC calculation worksheets, and Certificate of Origin.
Does USMCA exempt my goods from Section 122?
Yes. USMCA-qualifying goods are exempt from the 15% Section 122 surcharge.
How long does qualification take?
Simple goods: 1-2 weeks. Complex goods (deep BOM, multiple suppliers): 4-12 weeks for full documentation.
Get started
Run a USMCA RVC stress-test for your specific product. $4,500-$8,500 fixed-fee.